Optimizing Mainstreaming of Genetic Testing in Parallel With Ovarian and Endometrial Cancer Tumor Testing: How Do We...

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Germline genetic testing (GT) is crucial for ovarian cancer (OC) and endometrial cancer (EC) management.
• Uptake of recommended GT remains suboptimal due to various barriers.
• Integrating GT into routine oncology care, known as mainstreaming, is a strategy to improve access.

Purpose of the Study:

• To evaluate and optimize germline genetic testing (GT) processes within gynecologic oncology clinics.
• To assess the effectiveness of a mainstreaming approach combining somatic and germline GT.
• To identify barriers to GT uptake in patients with newly diagnosed OC and EC.

Main Methods:

• A quality improvement study was conducted in gynecologic surgery and medical oncology clinics.
• Patients with newly diagnosed OC/EC were identified for GT and data were collected.
• Qualitative themes regarding GT processes and barriers were reviewed.

Main Results:

• High GT rates were observed: 91% for OC and 75% for EC.
• Turnaround time for GT results was within 3 months for most patients.
• Identified barriers included missed recommendations, patient concerns (overwhelm, financial, privacy), and language issues.

Conclusions:

• Mainstreaming germline genetic testing (GT) alongside somatic testing improves uptake in OC/EC.
• Addressing identified barriers is essential for further improving GT rates.
• Piloting enhanced support, multi-point interventions, and digital multilingual consent is recommended.